# Study of YKST02 in Adults With Relapsed or Refractory Multiple Myeloma

> **NCT07695740** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Excyte Biopharma Ltd** · enrollment: 64 (estimated)

## Conditions studied

- Relapsed or Refractory Multiple Myeloma (RRMM)

## Interventions

- **DRUG:** YKST02

## Key facts

- **NCT ID:** NCT07695740
- **Lead sponsor:** Excyte Biopharma Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-09
- **Primary completion:** 2029-09
- **Final completion:** 2029-09
- **Target enrollment:** 64 (ESTIMATED)
- **Last updated:** 2026-07-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07695740

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07695740, "Study of YKST02 in Adults With Relapsed or Refractory Multiple Myeloma". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07695740. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*